首创EGFR-HER3双特异性抗体偶联药物iza-bren治疗经治转移性乳腺癌的Ib期研究
这项多中心Ib期研究纳入162例经治局部晚期或转移性乳腺癌患者,分HER2阳性、HR阳性/HER2阴性和三阴性三组,接受iza-bren 2.5 mg/kg静脉给药。主要终点安全性显示治疗相关不良事件发生率99.4%,≥3级77.8%,以血液学毒性为主;三组确认客观缓解率分别为46.3%、37.3%和34.8%,中位无进展生存期分别为5.8、7.0和5.8个月。
要点
- iza-bren在三种乳腺癌亚型中均显示临床意义的抗肿瘤活性。
- 安全性以血液学毒性为主,中性粒细胞减少55.6%、贫血42.0%。
- 未报告间质性肺病,但发生2例治疗相关死亡。
核心结论
- iza-bren在重度经治的转移性乳腺癌三种主要亚型中显示出总体可耐受的安全性和具有临床意义的抗肿瘤活性。
研究设计与样本
- 多中心Ib期研究纳入162例经治局部晚期或转移性乳腺癌患者,分HER2阳性(n=41)、HR阳性/HER2阴性(n=75)和三阴性(n=46)三组。
- 患者接受iza-bren 2.5 mg/kg静脉给药,每21天周期第1天和第8天给药,主要终点为安全性。
主要发现
- 全部162例患者均重度经治,69.8%接受过≥3线既往治疗。
- 治疗相关不良事件发生率99.4%,≥3级事件77.8%,主要为血液学毒性(中性粒细胞减少55.6%、贫血42.0%)。
- 发生2例治疗相关死亡(发热性中性粒细胞减少和颅内出血),未报告间质性肺病。
- 确认客观缓解率在HER2阳性组为46.3%(95%CI 30.7%–62.6%),HR阳性/HER2阴性组为37.3%(95%CI 26.4%–49.3%),三阴性组为34.8%(95%CI 21.4%–50.2%)。
- 中位无进展生存期在HER2阳性、HR阳性/HER2阴性和三阴性组分别为5.8、7.0和5.8个月。
临床怎么用
- iza-bren 2.5 mg/kg每21天周期第1天和第8天静脉给药方案在重度经治转移性乳腺癌中显示可管理的安全性,需重点监测血液学毒性。
局限性
- 本研究为Ib期单臂研究,样本量有限,各亚组样本量较小,疗效需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bispecific antibody-drug conjugates (ADCs) may overcome limitations of monospecific ADCs. We report results from a phase Ib study of iza-bren, a first-in-class epidermal growth factor receptor-human epidermal growth factor receptor 3 bispecific ADC, in patients with heavily pretreated locally advanced or metastatic breast cancer (MBC). PATIENTS AND METHODS: This multicenter study enrolled pretreated patients into three groups: human epidermal growth factor receptor 2 (HER2)-positive (n = 41), hormone receptor (HR)-positive/HER2-negative (n = 75), and triple-negative breast cancer (TNBC; n = 46). Patients received iza-bren 2.5 mg/kg i.v. on days 1 and 8 of each 21-day cycle. The primary endpoint was safety. RESULTS: All 162 enrolled patients were heavily pretreated (69.8% had ≥3 prior lines of therapy). Treatment-related adverse events occurred in 99.4% of patients, with grade ≥3 events observed in 77.8%, primarily hematological toxicities (neutropenia 55.6% and anemia 42.0%). Two treatment-related deaths occurred (febrile neutropenia and intracranial hemorrhage). No interstitial lung disease was reported. Confirmed objective response rates were 46.3% [95% confidence interval (CI) 30.7% to 62.6%] in HER2-positive, 37.3% (95% CI 26.4% to 49.3%) in HR-positive/HER2-negative, and 34.8% (95% CI 21.4% to 50.2%) in TNBC groups, with median progression-free survival of 5.8, 7.0, and 5.8 months, respectively. CONCLUSIONS: Iza-bren exhibited a generally tolerable safety profile and demonstrated clinically meaningful antitumor activity across three major subtypes of heavily pretreated MBC.
引用
- Zhang J, Meng Y, Du Y, et al. Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study. Ann Oncol. 2026. PMID: 42727637. doi:10.1016/j.annonc.2026.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。